New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2013
13:46 EDTOPXAOpexa Therapeutics held a conference call
Conference call to discuss the option and license agreement with Merck Serono for development of Tcelna for treatment of Multiple Sclerosis was held on February 5 at 8:30 am and has a webcasted replay available. Webcast Link
News For OPXA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 6, 2015
07:01 EDTOPXAOpexa granted new T-cell patents covering Tcelna
Opexa announced the issuance of four additional key patents covering its broad T-cell immunotherapy platform. The recent allowances bring the number of granted U.S. and international patents in Opexa's patent portfolio to 160, including in-licensed patents. The expansion of Opexa's intellectual property portfolio further strengthens the patent estate surrounding Tcelna, Opexa's personalized T-cell immunotherapy in development for the treatment of secondary progressive multiple sclerosis. Recently-granted European Patent Nos. 1546719, 2016414 and 2420833 are directed to Opexa's proprietary methods for preparing individualized T-cell vaccines, while European Patent No. 2363710 is directed to the autologous T-cell vaccine compositions themselves. The claims cover the use of particular immunodominant epitopes found in myelin basic protein, proteolipid protein and myelin oligodendrocyte protein in the preparation of such T-cell vaccines, as well as the identification and use of specific antigenic epitopes that are disease-relevant for individual patients from these and other polypeptide antigens.
September 28, 2015
07:01 EDTOPXAOpexa Therapeutics announces 1-for-8 reverse stock split
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use